Close X
Get more out of
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.

Click here if you're interested
Helping you make better health choices

What Doctors Don't Tell You

In shops now or delivered to your home from only £4.25 an issue!

September 2020 (Vol. 5 Issue 6)

Covid-19 "a huge commercial opportunity", says Pfizer
About the author: 
Bryan Hubbard

Covid-19 "a huge commercial opportunity", says Pfizer image

Drug giant Pfizer could earn up to £15bn from its Covid-19 vaccine. It's set a price of $19.50 per shot, and this is expected to be the industry standard for all pharmaceutical companies to follow.

The US government has placed a $1.95bn order for 100 million doses of the vaccine—but it's all contingent on the vaccine working. If it does, Pfizer is set for "a windfall" of $15bn, drug industry watchers predict.

But revenues could be double that if Pfizer progresses with its plans for a two-shot Covid vaccine, which its researchers are currently working on. The two-dose shot will cost $39.

US agencies are set to place an order for 500 million doses if the vaccine can be proven to work, and regulators will be setting the bar low to get a vaccine on the market as quickly as possible. The usual safety tests will be by-passed as those may take years of monitoring.

It's all great news for Pfizer shareholders, says industry analyst Randall Stanicky of RBC Capital Markets. The company's CEO, Albert Bourla, agrees. In a recent online conference, he said the virus presented "a huge commercial opportunity".

Pfizer isn't the only one in the race, hoping for massive revenue boosts, of course. Unusually, it hasn't sought government funding to help support its research for a vaccine, but those that have will be charging far less. AstraZeneca, for instance, is expected to charge around $4 per dose in recognition of government aid, and this is reckoned to be an 'at-cost' price with almost no profit added in.

Pfizer has set the price of a Covid shot, and especially for manufacturers who have funded their own research. Another vaccine front-runner, Moderna, was predicted to set its per-shot price at $50, but is now expected to fall in line with the Pfizer price.

Read all about it - but only in WDDTY

From now on, you won't be able to buy WDDTY in a store, as we are reverting to a subscription-only magazine. The reason goes to the very heart of what this publication stands for. As a newsstand title, we were being censored in all sorts of subtle and not-so-subtle ways by a retail trade that chose never to support press freedoms. But we don't want to stop you from getting vital information which is why we've curated this special subscription offer just for you. By subscribing you can still get direct access to all this information every month, via a subscription, as thousands of others do.


(Source:, July 27, 2020)

Support WDDTY

Help support us to hold the drugs companies, governments and the medical establishment accountable for what they do.


Latest Tweet


Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions..

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

© 2010 - 2020 WDDTY Publishing Ltd.
All Rights Reserved